Clinical use of botulinum toxins in oral and maxillofacial surgery

International Journal of Oral and Maxillofacial Surgery

Volumn 39, Issue 3, 2010, Pages 197-207

  Majid, O W ^a  

^a UNIVERSITY OF MOSUL   (Iraq)

Author keywords

botulinum; clinical use

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ALLERGIC REACTION; BLEPHAROSPASM; BLURRED VISION; BRUXISM; CAROTID ARTERY INJURY; CERVICAL DYSTONIA; CLINICAL TRIAL; CONTRACTURE; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRY EYE; DYSARTHRIA; DYSPHAGIA; ECCHYMOSIS; EDEMA; ERYTHEMA; EYELID EDEMA; FACE PAIN; FACIAL NERVE INJURY; FATIGUE; FLU LIKE SYNDROME; FOCAL DYSTONIA; FREY SYNDROME; HEADACHE; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERKINESIA; HYPERSALIVATION; HYPERTROPHIC SCAR; HYPESTHESIA; INFECTION; JAW DISEASE; MAXILLOFACIAL SURGERY; MIGRAINE; MOTOR DYSFUNCTION; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; MYOFASCIAL PAIN; NAUSEA; NERVE PARALYSIS; NONHUMAN; ORAL SURGERY; OROMANDIBULAR DYSTONIA; PAIN; PARALYSIS; PAROTID GLAND DISEASE; PERIOPERATIVE PERIOD; PRURITUS; PTOSIS; REVIEW; SALIVARY GLAND DISEASE; SIDE EFFECT; STRABISMUS; STUTTERING; SYNKINESIS; TARDIVE DYSKINESIA; TEMPOROMANDIBULAR JOINT DISORDER; TREMOR; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; VOICE CHANGE; WRINKLE; XEROSTOMIA;

BOTULINUM TOXIN TYPE A; FACIAL NERVE DISEASES; FACIAL PAIN; FACIAL PARALYSIS; HEADACHE; HUMANS; MOVEMENT DISORDERS; NEUROMUSCULAR AGENTS; NEUROMUSCULAR JUNCTION; ORAL SURGICAL PROCEDURES; SIALORRHEA; TEMPOROMANDIBULAR JOINT DISORDERS;

EID: 77549088809     PISSN: 09015027     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijom.2009.10.022     Document Type: Review

References (236)

1. Acquadro M., and Borodic G.E. Treatment of myofascial pain with botulinum toxin. Anesthesiology 80 (1994) 705-706
2. Adler C. Perioperative Use Of Botulinum Toxins. Abstracts Toxins 2008; Toxicon 51: 44.
3. Alster T., and Lupton J. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg 29 (2003) 516-518
4. Alvarez M, Grogan P: Efficacy and safety of Myobloc in headache prophylaxis: A retrospective observation. Abstracts Toxins 2008/Toxicon 51: p. 44.
5. Aoki K.R., and Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 8 suppl 5 (2001) 21-29
6. Aquilina P., Vickers R., and Mckellar G. Reduction of a chronic bilateral temporomandibular joint dislocation with intermaxillary fixation and botulinum toxin A. Br J Oral and Maxillofac Surg 42 (2004) 272-273
7. Armstrong M.W., Mountain R.E., and Murray J.A. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy. Clin Otolaryngol Allied Sci 21 (1996) 15-20
8. Arnaud S., Batifor D., and Goudot P. Nonsurgical management of traumatic injuries of the parotid gland and duct using type A botulinum toxin. Plast Reconstr Surg 117 (2006) 2426-2430
9. Bakke M., Møller E., Werdelin L.M., Dalager T., and Kitai N. Treatment of severe temporomandibular joint clicking with botulinum toxin in the lateral pterygoid muscle in two cases of anterior disc displacement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 (2005) 693-700
10. Bakke M., Werdelin L.M., Dalager T., Fuglsang-Frederiksen A., Prytz S., and Møller E. Reduced jaw opening from paradoxical activity of mandibular elevator muscles treated with botulinum toxin. Eur J Neurol 10 (2003) 695-699
11. Baumann L., Stezinger A., Vujevich J., Halem M., Bryde J., and Black L. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: A double-blinded, placebo- controlled trial. Dermatol Surg 29 (2003) 508-515
12. Bentsianov B., Francis A., and Blitzer A. Botulinum toxin treatment of temporomandibular disorders, masseteric hypertrophy, and cosmetic masseter reduction. Oper Tech Otolaryngol Head Neck Surg 15 (2004) 110-113
13. Blitzer A., Binder W.J., and Aviv J.E. The management of hyperfunctional facial lines with botulinum toxin: A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 123 (1997) 389-392
14. Blitzer A., Brin M.F., Greene P.E., and Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 98 (1989) 93-97
15. Blitzer A., and Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 111 (2001) 218-226
16. Boghen D., and Flanders M. Effectiveness of botulinum toxin in the treatment of spasmodic torticollis. Eur Neurol 33 (1993) 199-203
17. Borodic G., and Acquadro M. Management of facial pain with botulinum toxin in a tertiary pain clinic. Naunyn Schmiedebergs Arch Phannacol 365 Suppl 2 (2002) R14
18. Borodic G.E., and Acquadro M.A. The Use of Botulinum Toxin for the Treatment of Chronic Facial Pain. J Pain 3 (2002) 21-27
19. Borodic G.E., Pearce L.B., and Cheney M. Botulinum A toxin for treatment of aberrant facial nerve regeneration. Plast Reconstr Surg 91 (1993) 1042-1045
20. Botox Package Insert. Irvine, CA, Allergan, Inc.
21. Brandt F.S., and Bellman B. Cosmetic use of botulinum toxin Aexotoxin for the aging neck. Dermatol Surg 24 (1998) 1232-1234
22. Brashear A., Lew M.F., Dykstra D.D., Comella C.L., Factor S.A., and Rodnitzky R.L. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53 (1999) 1439-1446
23. Brin M.F. Botulinum toxin therapy: basic science and overview of other therapeutic applications. In: Blitzer A. (Ed). Management of facial lines and wrinkles (2000 p), Lippincott, Williams and Wilkins, Philadelphia 279-302
24. Brin M.F., Blitzer A., and Herman S. Orofaciomandibular and lingual dystonia. In: Moore A.P. (Ed). Handbook of Botulinim Toxin Treatment (1995), Blackwell Scientific, Oxford, England 151-163
25. Brin M.F., Blitzer A., and Herman S. Oromandibular dystonia: Treatment of 96 patients with botulinum toxin. In: Jankovic J., and Hallett M. (Eds). Therapy With Botulinum Toxin. (1994), Marcel Dekker, New York, NY 429-435
26. Brin M.F., Fahn S., and Moskowitz C. Localized injections of botulinum toxin for the treatment of focal dystonias and hemifacial spasm. Mov Disord 2 (1987) 237-254
27. Brin M.F., Lew M.F., Adler C.H., Comella C.L., Factor S.A., and Jankovic J. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53 (1999) 1431-1438
28. Bulstrode N.W., and Harrison D.H. The phenomenon of the late recovered Bell's palsy: treatment options to improve facial symmetry. Plast Reconstr Surg 115 (2005) 1466-1471
29. Bushara K.O. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment-botulinum toxin A injections of the parotid glands. Med Hypotheses 48 (1997) 337-339
30. Capaccio P., Cuccarini V., and Benicchio V. Treatment of iatrogenic submandibular sialocele with botulinum toxin. Case report. Br J Oral Maxillofac Surg 45 (2007) 415-417
31. Capaccio P., Paglia M., Minorati D., et al. Diagnosis and therapeutic management of iatrogenic parotid sialocele. Ann Otol Rhinol Laryngol 113 (2004) 562-564
32. Capaccio P., Torretta S., Osio M., and Minorati D. Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders. Am J Otol - Head and Neck Medicine and Surgery 29 (2008) 333-338
33. Carruthers A., and Carruthers J. Botulinum toxin type A: History and current cosmetic use in the upper face. Semin Cutan Med Surg 20 (2001) 71-84
34. Carruthers A: Facial aesthetic enhancement educational initiative. Chicago, IL, Faculty Training, July 2001; 13-15.
35. Carruthers J., and Carruthers A. The evolution of botulinum neurotoxin type A for cosmetic applications. J Cosmet Laser Ther 9 (2007) 186-193
36. Carruthers J., and Carruthers A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 18 (1992) 17-21
37. Carruthers J.A., Lowe N.J., Menter M.A., Gibson J., Nordquist M., and Mordaunt J. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46 (2002) 840-849
38. Carruthers S.J., Fagien S., and Matarasso S.L. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 114 6 Suppl (2004) 1S-22S
39. Cather J.C., Cather J.C., and Menter A. Update on botulinum toxin for facial aesthetics. Dermatol Clin 20 (2002) 749-761
40. Charles P.D., Davis T.L., Shannon K.M., Hook M.A., and Warner J.S. Tongue protrusion dystonia: treatment with botulinum toxin. South Med J 90 (1997) 522-525
41. Cherington M. Botulism: update and review. Semin Neurol 24 (2004) 155-163
42. Chua C.N., Quhill F., and Jones E. Treatment of aberrant facial nerve regeneration with botulinum toxin A. Orbit 23 (2004) 213-218
43. Clark R.P., and Berris C.E. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg 115 (2005) 573-574
44. Comella C.L., Jankovic J., Shannon K.M., Tsui J., Swenson M., and Leurgans S. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65 (2005) 1423-1429
45. Daelen B., Thorwirth V., and Koch A. Treatment of recurrent dislocation of the temporomandibular joint with type A botulinum toxin. Int J Oral Maxillofac Surg 26 (1997) 458-460
46. David A., Sherris M., and Holger G. Botulinum toxin to minimize facial scarring. Facial Plast Surg 18 (2002) 35-39
47. De Almeida A.T., Marques E., De Almeida J., Cunha T., and Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 33 1 Spec No. (2007) S37-S43
48. De Bont L.G., and Stegenga B. Pathology of temporomandibular joint internal derangement and osteoarthrosis. Int J Oral Maxillofac Surg 22 (1993) 71-74
49. De Paiva A., Meunier F.A., Molgo J., Aoki K.R., and Dolly J.O. Functional repair of motor endplates after botulinum neurotoxin type Apoisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 96 (1999) 3200-3205
50. Dembek Z.F., Smith L.A., and Rusnak J.M. Botulinum Toxin (chapter 16). In: Dembek Z.F. (Ed). Medical Aspects of Biological Warfare (2007), Office of The Surgeon General, Virginia 337-353
51. Dogu O., Apaydin D., Sevim S., Talas D.U., and Aral M. Ultrasoundguided versus blind intraparotid injections of botulinum toxin- A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 106 (2004) 93-96
52. Dressler D., and Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 49 (2003) 34-38
53. Dressler D, Mander GJ, Fink K. Equivalent potency of Xeomin and BOTOX. Abstracts Toxins 2008/Toxicon 51: 10.
54. Drobik C., and Laskawi R. Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol Stockh 115 (1995) 459-461
55. Drummond P. Mechanism of gustatory flushing in Frey's syndrome. Clin Auton Res 12 (2002) 144-146
56. Durham P.L., Cady R., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44 (2004) 35-42
57. Dworkin S.F. A model for pain mechanisms in myogenous temporomandibular disorders. Pain Forum 6 (1997) 166-169
58. Dworkin S.F., and Leresche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examinations and specifications, critique. J Craniomandib Disord Facial Oral Pain 6:301-55 (1992)
59. Ellies M., Gottstein U., and Rohrbach-Volland S. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope 114 (2004) 1856-1860
60. Ellies M., Laskawi R., and Gotz W. Immunohistochemical and morphometric investigations of the influence of botulinum toxin on the submandibular gland of the rat. Eur Arch Otorhinolaryngol 256 (1999) 148-152
61. Ellies M., Laskawi R., Rohrbach-Volland S., and Arglebe C. Up-todate report of botulinum toxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg 61 (2003) 454-457
62. Ellies M., Laskawi R., and Rohrbach-Volland S. Botulinum toxin to reduce saliva flow: Selected indications for ultrasound guided toxin application into salivary glands. Laryngoscope 112 (2002) 82-86
63. Ellies M., Laskawi R., and Tormahlen G. The effect of local injection of botulinum toxin A on the parotid gland of the rat: An immunohistochemical and morphometric study. J Oral Maxillofac Surg 58 (2000) 1251-1256
64. Ellis M.F., and Daniell M. An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis. Clin Exp Ophthalmol 29 (2001) 394-399
65. Elston J.S. Botulinum toxin A in clinical medicine. J Physiol (Paris) 84 (1990) 285-289
66. Erbguth F.J., and Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology 53 (1999) 1850-1853
67. Evers S., Vollmer-Haase J., Schwaag S., Rahmann A., Husstedt I.W., and Frese A. Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 24 (2004) 838-843
68. Fagien S., and Brandt F.S. Primary and adjunctive use of botulinum toxin type A (Botox) in facial aesthetic surgery: beyond the glabella. Clin Plast Surg 28 (2001) 127-148
69. Fagien S., Cox S.E., Finn J.C., Werschler W.P., and Kowalski J.W. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: A double-blind, randomized, placebo-controlled study. Dermatol Surg 33 1 Spec No. (2007) S2-S9
70. Flynn T.C. Myobloc. Dermatol Clin 22 (2004) 207-211
71. Flynn T.C. Update on botulinum toxin. Semin Cutan Med Surg 25 (2006) 115-121
72. Flynn T.C., Carruthers J., and Carruthers A. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 27 (2001) 703-708
73. Flynn T.C., and Clark R.E. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 29 (2003) 519-522
74. Foran P., Mohammed N., and Lisk G. Evaluation of the therapeutic usefulness of botulinum neurotoxins B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 278 (2003) 1363-1371
75. Frampton J.E., and Easthope S.E. Botulinum toxin A (Botox cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol 4 (2003) 709-725
76. Franz D.R., Pitt L.M., Clayton M.A., Hanes M.A., and Rose K.J. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In: DasGupta B.R. (Ed). Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects (1993), Plenum Press, New York, NY 473-476
77. Freeman S.R., and Cohen J.L. New Neurotoxins on the Horizon. Aesthetic Surg J 28 (2008) 325-330
78. Freund B., and Schwartz M. Intramuscular injection of botulinum toxin as an adjunct to arthrocentesis of the temporomandibular joint: preliminary observations. Br J Oral Maxillofac Surg 41 (2003) 351-352
79. Freund B., and Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain 4 (2003) 159-165
80. Freund B., Schwartz M., and Symington J.M. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral and Maxillofac Surg 38 (2000) 466-471
81. Freund B., Schwartz M., and Symington J.M. The Use of Botulinum Toxin for the Treatment of Temporomandibular Disorders: Preliminary Findings. J Oral Maxillofac Surg 57 (1999) 916-920
82. Freund B.J., and Schwartz M. The use of botulinum toxin for the treatment of temporomandibular disorder. Oral Health 88 (1998) 32-37
83. Freund B.J., and Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache 42 (2002) 1033-1037
84. Freund B.J., and Schwartz M. Treatment of chronic cervical-associated headache with botulinum toxin A: A pilot study. Headache 40 (2000) 231-236
85. Frost De, and Kendell B.D. Part II. The use of arthrocentesis for treatment of temporomandibular joint disorders. J Oral Maxillofac Surg 57 (1999) 583-587
86. Giess R., Naumann M., and Werner E. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 69 (2000) 121-123
87. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 46 (1982) 86-94
88. Glogau R.G. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: Results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 33 1 Spec No. (2007) S76-S80
89. Gusek-Schneider G.C., and Erbguth F. Protective ptosis by botulinum A toxin injection in corneal affectations. Klin Monatsbl Augenheilkd 213 (1998) 15-22
90. Hallett M. One man's poison-Clinical applications of botulinum toxin. N Engl J Med 341 (1999) 118-120
91. Halpern J.L., Smith L.A., Seamon K.B., Groover K.A., and Habig W.H. Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody. Infect Immun. 57 (1989) 18-22
92. Hatheway C.L. Clostridium botulinum and other clostridia that produce botulinum neurotoxins. In: Hauschild A.H.W., and Dodds K.L. (Eds). Clostridium botulinum-Ecology and Control in Foods (1992), Marcel Dekker, Inc, New York, NY 3-10
93. Hegedus F., Diecidue R., Taub D., and Nyirady J. Non-surgical treatment modalities of facial photodamage: practical knowledge for the oral and maxillofacial professional. Int. J. Oral Maxillofac. Surg. 35 (2006) 389-398
94. Hennings J.M.H., Krause E., Bötzel K., and Wetter T.C. Successful treatment of tardive lingual dystonia with botulinum toxin: Case report and review of the literature. Progress in Neuro-Psychopharmacology & Biological Psychiatry 32 (2008) 1167-1171
95. Hermanowicz N., and Truong D.D. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope 101 (1991) 1216-1218
96. Herrero B.A., Ecklung A.E., Streett C.S., Ford D.F., and King J.K. Experimental botulism in monkeys-Aclinical pathological study. Exp Mol Pathol. 6 (1967) 84-95
97. Hofmann R.J. Treatment of Frey's syndrome (gustatory sweating) and 'crocodile tears' (gustatory epiphora) with purified botulinum toxin. Ophthalmic Plast Reconstr Surg 16 (2000) 289-291
98. Hogan P., Charles D., Watts M.W., and Massey J.M. Severity and Impact of Xerostomia in Patients Treated with Botulinum Toxin Type B for Cervical Dystonia: Observations on the Quality of Life of Patients with Xerostomia. Curr Ther Res Clin Exp. 65 (2004) 161-171
99. Holmes J.M., Beck R.W., Kip K.E., Droste P.J., and Leske D.A. Botulinum toxin treatment versus conservative management in the acute traumatic sixth nerve palsy or paresis. J AAPOS 4 (2000) 145-149
100. Huang W., Foster J.A., and Rogachefsky A.S. Pharmacology of botulinum toxin. J Am Acad Dermatol 43 2 Pt 1 (2000) 249-259
101. Stefan K.A., and Konstantinovic V.S. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: an evidence-based review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 (2007) e1-e11
102. Ing E.B., Sullivan T.J., Clarke M.P., and Buncic J.R. Oculomotor nerve palsies in children. J Pediatr Ophthalmol Strabismus 29 (1992) 331-336
103. Isaac A.M. Unilateral temporalis muscle hypertrophy managed with botulinum toxin type A. Br J Oral Maxillofac Surg 38 (2000) 571-572
104. Ivanhoe C.B., Lai J.M., and Francisco G.E. Bruxism after brain injury: successful treatment with botulinum toxin- A. Arch Phys Med Rehabil 78 (1997) 1272-1273
105. Jankovic J., and Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37 (1987) 616-623
106. Jongerius P.H., Van Den Hoogen F., Van Limbeek J., Gabreëls F.J., Van Hulst K., and Rotteveel J.J. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 114 (2004) 620-627
107. Jost Wh, Blumel J., and Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 67 (2007) 669-683
108. Kane M.A. Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg 103 (1999) 656-663
109. Kerr N.C., and Hoehn M.B. Botulinum toxin for sixth nerve palsies in children with brain tumors. J AAPOS 5 (2001) 21-25
110. Krohel G.B., Cipollo C.I., and Gadipatti K. Contralateral botulinum toxin injections improve drinking ability and facial symmetry in patients with facial paralysis. Am J Ophthalmol 135 (2005) 540
111. Laccourreye O., Muscatelo L., and Naude C. Botulinum toxin type A for Frey's syndrome: a preliminary prospective study. Ann Otol Rhinol Laryngol 107 (1998) 52-55
112. Lagalla G., Millevolte M., Capecci M., Provinciali L., and Ceravolo M.G. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 21 (2006) 121-125
113. Lamanna C. The most poisonous poison. Science 130 (1959) 763-772
114. Lang A.M. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil 84 3 Suppl 1 (2003) S69-73 [quiz S4-5]
115. Larheim Ta, Westesson Pl, and Sano T. Temporomandibular joint disk displacement: comparison in asymptomatic volunteers and patients. Radiology 218 (2001) 428-432
116. Laskawi R., Drobik C., and Schonebeck C. Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome). Laryngoscope 108 (1998) 381-384
117. Laskawi R., Rohrbach S., Rödel R., and Surgical. Nonsurgical Treatment Options in Patients With Movement Disorders of the Platysma. J Oral Maxillofac Surg 60 (2002) 157-162
118. Lew M.F., Adornato B.T., and Duane D.D. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49 (1997) 701-707
119. Lew M.F., Brashear A., and Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: Summary of three controlled clinical trials. Neurology 55 12 Suppl 5 (2000) S29-S35
120. Lger G., Anthoy E., and Brisse T. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc 81 (2006) 1023-1028
121. Liesegang TJ, Skuta GL, Cantor LB. Special forms of strabismus. In: Simon JW, Buckly EG, Drack AV, et al, (eds.) Pediatric Ophthalmology and Strabismus. San Francisco (CA): American Academy of Ophthalmology; 2004-2005. p. 140-41.
122. Lipp A., Trottenberg T., Schink T., Kupsch A., and Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61 (2003) 1279-1281
123. Lovely F.W., and Copeland R.A. Reduction eminoplasty for chronic recurrent luxation of the temporomandibular joint. J Can Dent Assoc 3 (1981) 179-184
124. Lowe N.J., Maxwell A., and Harper H. Botulinum A exotoxin for glabellar folds: A double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol 35 (1996) 569-572
125. Lowe N.J., Yamauchi P.S., Lask G.P., Patnaik R., and Moore D. Botulinum toxins types A and B for brow furrows: Preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 4 (2002) 15-18
126. Lowe P., Patnaik R., and Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: A double-blind, randomized study. J Am Acad Dermatol 55 (2006) 975-980
127. Lowe P.L., Patnaik R., and Lowe N.J. A comparison of two botulinum type A toxin preparations for the treatment of glabellar lines: Double-blind, randomized, pilot study. Dermatol Surg 31 (2005) 1651-1654
128. Lundh H., and Westesson P.L. Clinical signs of temporomandibular joint internal derangement in adults. An epidemiologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 72 (1991) 637-641
129. Mancini F., Zangaglia R., Cristina S., Sommaruga M.G., Martignoni E., Nappi G., and Pacchetti C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18 (2003) 685-688
130. Marchese-Ragona R., De Filippis C., and Staffieri A. Parotid gland fistula: treatment with botulinum toxin. Plast Reconstr Surg 107 (2001) 886-887
131. Marchese-Ragona R., Galzignato P.F., and Marioni G. Endoscopic diagnosis of rhino-parotid fistula and successful treatment with botulinum toxin. Laryngoscope 115 (2005) 2062-2064
132. Marchese-Ragona R., Marioni G., and Restivo A.D. The role of botulinum toxin in postparotidectomy fistula treatment. A technical note. Am J Otolaryngol 27 (2006) 221-224
133. Marina S, Vasić M, Pekmezović T, Kostić V. Botulinum toxin in the treatment of sialorrhea. Abstracts Toxins/Toxicon 2008; 51: 50.
134. Matarasso A., Matarasso S.L., and Brandt F.S. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 103 (1999) 645-652
135. Matarasso S.L. Comparison of botulinum toxin types A and B: A bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 29 (2003) 7-13
136. Mazow M.L. Third cranial nerve palsy: Diagnosis and management strategies. In: Rosenbaum A.L., and Santiago A.P. (Eds). Clinical Strabismus Management: Principles and Surgical Technique (1999), W.B. Saunders, Philadelphia (PA) 251-258
137. Mckellar G., and Lorentz I. The use of botulinum-toxin in the treatment of oromandibular dystonias and fractures of the mandibular condyle. Aust N Z J Med 22 (1992) 428
138. Metai M. Morphological and functional-changes in masseter after administration of botulinum toxin for treatment of masseteric hypertrophy. J Dent Res 75 (1996 May) 1164
139. Metz H.S., and Mazow M. Botulinum toxin treatment of acute sixth and third nerve palsy. Graefes Arch Clin Exp Ophthalmol 226 (1988) 141-144
140. Middlebrook J.L., and Franz D.R. Botulinum toxins. In: Sidell F.R., Takafuji E.T., and Franz D.R. (Eds). Textbook of Military Medicine, Part I: Warfare, Weaponry, and the Casualty-Medical Aspects of Chemical and Biological Warfare (1997), Department of the Army, Office of The Surgeon General, Borden Institute, Washington, DC 643-654 Chap 33
141. Miller S.C., and Firestone J.M. Psychosomatic factors in the aetiology of periodontal diseases. Am J Orthodont Oral Surg 33 (1947) 675-680
142. Montoya F.J., Riddell C.E., Caesar R., and Hague S. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye 16 (2002) 705-709
143. Moore A.P., and Wood C.G. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin A. Br Dent J 183 (1997) 415-417
144. Moore A.P., and Wood G.D. The Medical Management of Masseteric Hypertrophy With Botulinum Toxin Type A. Br J Oral Maxillofac Surg 32 (1994) 26-28
145. Moreau M.S., Cauhepe C., Magues J.P., and Senard J.M. A double-blind, randomized, comparative study of Dysport vs. BOTOX in primary palmar hyperhidrosis. Br J Dermatol 149 (2003) 1041-1045
146. Niamtu J., and Campbell R.L. The anesthetic skin patch for topical cutaneous anesthesia. J Oral Maxillofac Surg 42 (1984) 839-840
147. Niamtu J. Aesthetic uses of botulinum toxin A. J Oral Maxillofac Surg 57 (1999) 1228-1233
148. Niamtu J. Botulinum Toxin A: A Review of 1,085 Oral and Maxillofacial Patient Treatments. J Oral Maxillofac Surg 61 (2003) 317-324
149. Niamtu J. Cosmetic facial surgery. Oral Maxillofac Surg Clin North Am 12 (2000) 595
150. O'day J. Use of botulinum toxin in neuro-opthalmology. Curr Opin Opthalmol 12 (2001) 419-422
151. Ohishi I. Oral toxicities of Clostridium botulinum type Aand Btoxins from different strains. Infect Immun. 43 (1984) 487-490
152. Okeson J.P. Orofacial Pain: Guidelines for Assessment, Diagnosis and Management (1996), Quintessence Co., Chicago p. 45-52
153. Ondo W.G., Hunter C., and Moore W. A double-blind placebocontrolled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62 (2004) 37-40
154. Padberg M., De Bruijn S.F., De Haan R.J., and Tavy D.L. Treatment of chronic tension-type headache with botulinum toxin: a doubleblind, placebo-controlled clinical trial. Cephalalgia 24 (2004) 675-680
155. Pal P.K., Calne D.B., Calne S., and Tsui J.K. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 54 (2000) 244-247
156. Pappert E., Leong M., and Royal M. Botulinum toxin type B compared with type A in the treatment of patients with cervical dystonia: results from a randomized, double-blind non-inferiority study. Neurology 66 Suppl (2006) A252
157. Park Y.C., Lim J.K., Lee D.K., and Yi S.D. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 8 (1993) 334-340
158. Pérez D.M., and Espiga P.G. Recurrent Temporomandibular Joint Dislocation Treated With Botulinum Toxin: Report of 3 Cases. J Oral Maxillofac Surg 62 (2004) 244-246
159. Poewe W., Deuschl G., Nebe A., Feifel E., Wissel J., and Benecke R. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 64 (1998) 13-17
160. Porta M., Gamba M., and Bertacci G. Treatment of sialorrhea with ultrasound guided botulinum toxin type A injections in patients with neurological disorders. J Neurol Neurosurg Psychiatry 70 (2001) 538-540
161. Quah B.L., Ling Y.L., Cheong P.Y., and Balakrishnan V. A review of 5 years' experience in the use of botulinium toxin A in the treatment of sixth cranial nerve palsy at the Singapore National Eye Centre. Singapore Med J 40 (1999) 405-409
162. Racette B.A., Good L., Sagitto S., and Perlmutter J.S. Botulinum toxin B reduces sialorrhea in Parkinsonism. Mov Disrod 18 (2003) 1059-1061
163. Ramirez A.L., Reeck J., and Maas C.S. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 126 (2002) 459-467
164. Ramirez OM, Maillard GF, Musolas A. The extended subperiosteal face lift: a definitive soft-tissue remodeling for facial rejuvenation. Plast Reconstr Surg 88:227-36, discussion 1991; 237-8.
165. Redding G.R., Rubright W.C., and Zimmerman S.O. Incidence of brnxism. J Dent Res 45 (1966) 1198-1204
166. Relja M., and Telarovic S. Botulinum toxin in tension-type headache. J Neurol 251 Suppl 1 (2004) I12-I14
167. Restivo D.A., Lanza S., and Patti F. Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology 59 (2002) 1971-1973
168. Rieder C.R., Schestatsky P., Socal M.P., Monte T.L., Fricke D., and Costa J. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 30 (2007) 39-42
169. Riemann R., Pfennigsdorf S., and Riemann E. Successful treatment of crocodile tears by injection of botulinum toxin into the lacrimal gland: a case report. Ophthalmology 106 (1999) 2322-2324
170. Rijsdijk B.A. Botulinum toxin Type A treatment of cosmetically disturbing masseteric hypertrophy (DUT). Ned Tijdschr Geneeskd 142 (1998) 529-532 (Abstract)
171. Rollnik J.D., Tanneberger O., Schubert M., Schneider U., and Dengler R. Treatment of tension-type headache with botulinum toxin type A: A double-blind, placebo-controlled study. Headache 40 (2000) 300-305
172. Rowe N.L., and Williams L.I. Fracture of the zygomatic complex and orbit. In: Williams L.I. (Ed). Rowe and Williams' Maxillofacial injuries. 2nd edition Vol. 1 (1994), Churchill Livingstone 515
173. Saad N., and Lee J. The role of botulinum toxin in third nerve palsy. Aust N Z J Ophthalmol 20 (1992) 121-127
174. Sadick N. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles. Dermatol Surg 29 (2003) 501-507
175. Sadick N.S. Botulinum toxin type B for glabellar wrinkles: A prospective open-label response study. Dermatol Surg 28 (2002) 817-821
176. Sadick N.S., and Matarasso S.L. Comparison of botulinum toxins A and B in the treatment of facial rhytides. Dermatol Clin 22 (2004) 221-226
177. Sadiq S.A., and Downes R.N. A clinical algorithm for the management of facial nerve palsy from an oculoplastic perspective. Eye 12 Pt 2 (1998) 219-223
178. Said S.Z., Meshkinpour A., Carruthers A., and Carruthers J. Botulinum toxin A: its expanding role in dermatology and esthetics. Am J Clin Dermatol 4 (2003) 609-616
179. Savarese R., Diamond M., Elovic E., and Millis S.R. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil 83 (2004) 304-311
180. Schantz E.J., and Johnson E.A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 56 (1992) 80-99
181. Schmitt W.J., Slowey E., Fravi N., Weber S., and Burgunder J.M. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 41 (2001) 658-664
182. Schneider S.A., Aggarwal A., Bhatt M., Dupont E., Tisch S., and Limousin P. Severe tongue protrusion dystonia - clinical syndromes and possible treatment. Neurology 67 (2006) 940-943
183. Schulte-Mattler W.J., and Krack P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 109 1-2 (2004) 110-114
184. Schulte-Mattler W.J., Wieser T., and Zierz S. Treatment of tensiontype headache with botulinum toxin: a pilot study. Eur J Med Res 4 (1999) 183-186
185. Schwaag S., Vollmer-Haase J., Rahman A., Frese A., Husstedt Iw, and Evers S. Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 24 (2004) 838-843
186. Scott A.B. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 79 (1981) 734-770
187. Scott A.B., Rosenbaum A., and Collins C.C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12 (1973) 924-927
188. Scott A.B., and Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 3 (1988) 333-335
189. Scott K.R., Kothari M.J., Venkatesh Y.S., Murphy T., and Simmons Z. Parotid gland injections of botulinum toxin A are effective in treating sialorrhea in amyotrophic lateral sclerosis. J Clin Neuromuscul Dis 7 (2005) 62-65
190. Sen P., and Papesch M. Botulinum Toxin A for the Management of Gustatory Sweating. Otolaryngol Head and Neck Surg 139 (2008) 126
191. Senno R.G., Marciniak C.M., Olsson A.B., Esposito N., and Duraski S.A. Botulinum Toxin Type A in the Treatment of Temporomandibular Joint Dislocation in an Adult With Anoxic Brain Injury: A Case Report. (Abstract). Arch Phys Med Rehabil 84 (2003) E8
192. Sessle B.J. Neural mechanisms and neuroplasticity related to deep craniofacial pain. Pain Forum 6 (1997) 173-175
193. Shaari C.M. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 101 (1991) 960-963
194. Shaari C.M., Bei-Lian W.U., Biller H.F., Chuang S.-K., and Sanders I. Botulinum toxin decreases the salivation from canine submandibular glands. Otolaryngol Head Neck Surg 118 (1998) 452-457
195. Shorey C.W., and Campbell J.H. Dislocation of the temporomandibular joint (Review). Oral Med Oral Pathol Oral Radiol Endod 89 (2000) 662-668
196. Silberstein S., Mathew N., Saper J., and Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 40 (2000) 445-450
197. Smet-Dieleman H., Van De Heyning P.H., and Tassignon M.J. Botulinum A toxin injection in patients with facial nerve palsy. Acta Otorhinolaryngol Belg 47 (1993) 359-363
198. Smith H.S., Audette J., and Royal M.A. Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain 18 suppl (2002) S147-S154
199. Smith L.D.S. The occurrence of Clostridium botulinum and Clostridium tetani in the soil of the United States. Health Lab Sci. 15 (1978) 74-80
200. Sobel J., Tucker N., and Sulka A. Foodborne botulism in the United States, 1900-2000. Emerg Infect Dis. 10 (2004) 1606-1611
201. Song P.C., Schwartz J., and Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis 13 (2007) 253-260
202. Spillane K.S., Shelton J.E., and Hasty M.F. Stroke-induced trismus in a pediatric patient: Long-term resolution with botulinum toxin A. Am J Phys Med Rehabil 82 (2003) 485-488
203. Stell R., Coleman R., Thompson P., and Marsden C.D. Botulinum toxin treatment of spasmodic torticollis. BMJ 297 (1988) 616
204. Stern R.S. Clinical practice. Treatment of photoaging. N Engl J Med 350 (2004) 1526-1534
205. Stip E., Faughnan M., Desjardin I., and Labrecque R. Botulinum toxin in a case of severe tardive dyskinesia mixed with dystonia. Br J Psychiatry 161 (1992) 867-868
206. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev. 44 (1980) 419-448
207. Suskind D.L., and Tilton A. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 112 (2002) 73-81
208. Svenson P. Pain mechanisms in myogenous temporomandibular disorders. Pain Forum 6 (1997) 158-165
209. Talarico-Filho S., Mendonça D.O., Nascimento M., Sperandeo D.E., Macedo F., and Sanctis D.E. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary Axillary hyperhidrosis. Dermatol Surg 33 1 Spec No. (2007) S44-S50
210. Talebnejad M.R., Sharifi M., and Nowroozzadeh M.H. The role of Botulinum toxin in management of acute traumatic third-nerve palsy. J AAPOS 12 (2008) 510-513
211. Tan E.K., Fook-Chong S., Lum S.Y., and Lim E. Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). J Neurol Sci 219 1-2 (2004) 151-155
212. Tan E.K., and Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 131 (2000) 211-216
213. Tan E.K., and Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 53 (1999) 2102-2107
214. Tan E.K., Lo Y.L., Seah A., and Auchus A.P. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci 190 (2001) 95-97
215. Tang X., and Wan X. Comparison of Botox with a Chinese type A botulinum toxin. Chin Med J (Engl) 113 (2000) 794-798
216. Ting P.T., and Freiman A. The story of Clostridium botulinum: From food poisoning to BOTOX. Clin Med 4 (2004) 258-261
217. Titner R., and Jankovic J. Botulinum toxin type A in the management of oromandibular dystonia and bruxism. In: Brin M.F., Hallet M., and Jankovic J. (Eds). Scientific and therapeutic aspects of botulinum toxin (2002), Williams and Wilkins, Philadelphia: Lippincott 343-356
218. Tokuno T., Nakazawa K., Yoshida S., Matsumoto S., Shingu T., and Sato S. Primary oculomotor nerve palsy due to head injury: analysis of 10 cases. No Shinkei Geka 23 (1995) 497-501
219. Truong D.D., Hermanowicz N., and Rontal M. Botulinum toxin in treatment of tardive dyskinetic syndrome. J Clin Psychopharmacol 10 (1990) 438-439
220. Truong D.D., and Jost W.H. Botulinum toxin: Clinical use (Review). Parkinsonism and Related Disorders 12 (2006) 331-355
221. Van Zandijcke M., and Marchau M.M. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry 53 (1990) 530
222. Vargas H., Galatti L.T., and Parnes S.M. A pilot study evaluationing the treatment of postparotidectomy sialoceles with botulinum toxin type A. Arch Otolaryngol Head Neck Surg 126 (2000) 421-424
223. Varma J.K., and Katsitadze G. Moiscrafishvili. Signs and symptoms predictive of death in patients with foodborne botulism-Republic of Georgia, 1980-2002. Clin Infect Dis. 39 (2004) 357-362
224. Verma A., and Steele J. Botulinum toxin improves sialorrhea and quality of living in bulbaramyotrophic lateral sclerosis. Muscle Nerve 34 (2006) 235-237
225. Von Lindern J.J., Niederhagen B., Berge S., and Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg 61 (2003) 774-778
226. Watanabe Y., Bakheit A., and Mclellan D. A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity. Disabil Rehabil: Int Multidiscip J 20 (1998) 62-65
227. Widmer C.G. Idiopathic masticatory muscle pain. Pain Forum 6 (1997) 170-172
228. Winterholler M.G., Erbguth F.J., Wolf S., and Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach [comment]. J Neurol Neurosurg Psychiatry 70 (2001) 417-418
229. Wohlfarth K., Muller C., Sassin I., Comes G., and Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 30 (2007) 86-94
230. Yao C.-C., Chao C.-H., and Hong Y.-K. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 175 (2006) 1158-1163
231. Yasufuku-Takano J., Sakurai M., Kanazawa I., and Nagaoka M. Successful treatment of intractable tardive dyskinesia with botulinum toxin. J Neurol Neurosurg Psychiatry 58 (1995) 511-512
232. Yoshimura D.M., Aminoff M.J., Tami T.A., and Scott A.B. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 15 (1992) 1045-1049
233. Zhibo X., and Miaobo Z. Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scar. J Plast Reconstr Aesthet Surg 61 (2008) 1128-1129
234. Zhibo X., and Miaobo Z. Potential therapeutical effects of botulinum toxin type A in keloid management. Medical Hypotheses 71 (2008) 623
235. Ziegler C.M., Haag C., and Mühling J. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injections. Clin Oral Invest 7 (2003) 52-55
236. Zwart J.A., Bovim G., Sand T., and Sjaastad O. Tension headache: botulinum toxin paralysis of temporal muscles. Headache 34 (1994) 458-462